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HIV-associated nephropathy – an 
increasing clinical problem
While highly active antiretroviral therapy (HAART) has reduced 
the morbidity and mortality of HIV-infected people, HIV-associated 
chronic diseases place an increasingly heavy burden on health 
systems in South Africa (SA). HIV-associated nephropathy (HIVAN) 
is the leading cause of end-stage renal failure (ESRF) in HIV-infected 
patients in SA.1,2 In the USA, it is the fourth most common cause 
of ESRF among 20 - 64-year-old HIV-infected black patients (after 
diabetes, hypertension and chronic glomerulonephritis).3 
A study at Chris Hani Baragwanath Hospital in Johannesburg 
demonstrated HIVAN in 27% of 455 HIV patients,4 while a study 
in Durban found HIVAN in 83% of cases of ESRF in antiretroviral-
naïve HIV-infected patients.2 Based on approximately 5.5 million 
people living with HIV/AIDS in SA, an estimated 10% will develop 
ESRF, despite standard antiretroviral therapy (ART). Some 550 000 
individuals may be expected to require renal replacement therapy 
(RRT) comprising dialysis and transplantation, considerably more 
than the SA population currently receiving dialysis, and exceeding 
the health service renal replacement capacity. Compounding this 
potentially massive increase in RRT candidates, is the shortage of 
deceased donor organs; at Groote Schuur Hospital (GSH) the number 
of deceased donor referrals has halved in the past 10 years.
Criteria for renal replacement therapy 
in low- to middle-income countries 
A lack of dialysis slots exists worldwide. Emerging economies 
such as SA experience the greatest pressure of competition for 
haemo- and peritoneal dialysis slots.5 GSH has facilities for only 
100 haemodialysis and 50 peritoneal dialysis patients in its chronic 
dialysis programme at any one time, with concomitant pressure 
to transplant patients and free dialysis space. A strategy has been 
adopted to offer RRT to the healthiest and the young. As in 
other centres in SA, prospective patients are presented at weekly 
multidisciplinary assessment meetings to decide whether they are 
suitable for renal replacement.6 Criteria, including fitness to undergo 
renal transplantation, age, co-morbidity, social circumstances and 
psychological state, are strictly applied. Patients aged >60 years are 
refused RRT and there is preferential allocation to patients without 
accompanying chronic co-morbidity. Determining the most ethical 
allocation requires considerations of justice and equity. Moosa and 
Kidd draw attention to the dangers and injustice inherent in such a 
rationing of this scarce resource.6
Before deciding to commence HIV-positive-to-positive 
transplantation at GSH, HIV-infected patients with ESRF were 
believed to be poor transplant candidates and were not accepted 
for RRT. Moreover, until 2004, HIV-infected patients were deemed 
unsuitable for renal transplantation owing to the lack of an ART 
programme, and the dangers of using immunosuppressive anti-
rejection drugs in the absence of HAART. This concern has abated 
as good outcomes have been confirmed after transplantation in HIV-
infected patients receiving HAART.7,8
Solid organ transplantation in HIV-
infected patients
Studies from the USA have shown that there is no difference in 
patient outcome, graft survival and opportunistic infection rates 
in HIV-infected patients undergoing transplant, compared with 
HIV-seronegative patients.9-11 Many immunosuppressive drugs 
controlling rejection in transplant patients retard HIV replication;12,13 
mycophenolate mofetil acts synergistically with some nucleoside 
analogues, and sirolimus down-regulates the CCR5 co-receptor on 
CD4+ T-cells, which plays a vital role in entry of HIV into the cell.14,15 
More rapid immune reconstitution has also been reported in HIV-
positive patients treated with cyclosporine (as anti-rejection therapy) 
and HAART versus HAART alone.16
With expanding access to HAART, practice in South Africa now 
permits allocation of RRT to HIV-infected patients. However, the 
increasing numbers of patients, the insufficiency of available dialysis 
slots and the lack of HIV-negative organ donors, severely limits the 
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HIV infection was previously an absolute contraindication to 
renal transplantation. However, with the advent of highly active 
antiretroviral therapy (HAART), renal transplantation using HIV-
negative donor kidneys has successfully been employed for HIV-
infected patients with end-stage renal failure. In resource-limited 
countries, places on dialysis programmes are severely restricted; 
HIV-infected patients, like many others with co-morbidity, are 
often denied treatment. Kidneys (and other organs) from HIV-
infected deceased donors are discarded. The transplantation of 
HIV-positive donor kidneys to HIV-infected recipients is now a 
viable alternative to chronic dialysis or transplantation of HIV-
negative donor kidneys. This significantly increases the pool of 
donor kidneys to the advantage of HIV-positive and -negative 
patients. Arguments are presented that led to our initiation of 
renal transplantation from HIV-positive deceased donors to HIV-
positive recipients at Groote Schuur Hospital, Cape Town.
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ability to offer RRT (even to HIV-negative patients).6 We therefore 
concluded that transplanting a kidney from an HIV-infected donor 
(that would otherwise have been discarded) into an HIV-positive 
recipient represented a viable option, given the potentially large pool 
of HIV-infected donors (10 - 20% HIV seroprevalence in potential 
donors referred to Transplant Co-ordinators in Cape Town and 
Johannesburg).
However, there are several theoretical concerns to this approach. 
Firstly, there is the risk that the donor kidney will act as a ‘Trojan 
horse’, super-infecting the recipient with a recombinant form of 
virus or with virus of a different clade.17,18 However, as HAART is 
equally effective in suppressing all clades of HIV, replication of super-
infecting HIV should rapidly be suppressed, particularly as it is our 
practice that the recipient is prescribed a protease inhibitor-based 
regimen following transplantation. There is a further theoretical risk 
that the donor will transmit drug-resistant virus.19  Although this risk 
is very small at this stage of the HIV epidemic in SA, we accept that 
resistance rates will inevitably increase over time, as more patients 
commence HAART and fail first- and second-line therapy. Future 
strategies to suppress potentially resistant virus would include the use 
of donor virus genotyping to inform appropriate ART prescribing. 
The donor kidney may also act as a ‘Trojan horse’ for other infectious 
diseases such as tuberculosis, cytomegalovirus, etc. To obviate this, 
we measure the urine protein-creatinine ratio and perform a baseline 
renal biopsy to detect donor renal disease before implantation.
In 2010 we reported our experience with the first 4 kidney 
transplants from HIV-positive donors to HIV-positive recipients.20 
Since then, 10 more HIV-positive to HIV-positive renal transplants 
have been performed (at GSH and the UCT Private Hospital). In all 
patients, surgery was uncomplicated. Following transplantation, ART 
was recommenced on day 1 or day 2 and all patients received anti-
thymocyte globulin or thymoglobulin induction therapy and an anti-
rejection regimen consisting of mycophenolate mofetil, tacrolimus 
and prednisone. All patients are currently 1 - 4 years post-transplant 
and have undetectable viral loads (<50 copies/ml).
In conclusion, we have shown that transplanting HIV-infected 
patients with ESRF with kidneys from HIV-positive donors represents 
a significant advance, benefiting patients with ESRF due to HIVAN, 
within our resource-constrained context.
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